• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肺癌治疗:个性化医疗的作用。

Lung Cancer Therapy: The Role of Personalized Medicine.

作者信息

Ramos Raquel, Moura Conceição Souto, Costa Mariana, Lamas Nuno Jorge, Correia Renato, Garcez Diogo, Pereira José Miguel, Lindahl Thomas, Sousa Carlos, Vale Nuno

机构信息

PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.

RISE-Health, Department of Pathology, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal.

出版信息

Cancers (Basel). 2025 Feb 21;17(5):725. doi: 10.3390/cancers17050725.

DOI:10.3390/cancers17050725
PMID:40075573
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11899562/
Abstract

Lung cancer is the deadliest cancer worldwide, exhibiting the highest incidence rate among all cancer types. Poor outcomes often characterize this cancer as it is commonly diagnosed in advanced stages due to its unspecific symptoms. After diagnosis, the therapeutic choice is a crucial stage that profoundly affects patients' survival. Treatment choices for lung cancer must be made carefully, acknowledging the histological type and genetic characteristics of the tumor. Non-small cell lung cancer, the most common and complex type, has a high mutational burden, making next-generation sequencing (NGS) essential for identifying specific mutations and guiding treatment. With several approved targeted therapies already available, this approach highlights the critical role of personalized medicine in lung cancer care. Despite the current therapeutic pipeline, research trying to develop new tailored drugs considering individual patient characteristics has evolved over the years. This article aims to outline the current therapeutic approach for each type of lung cancer and present the latest insights into emerging therapies, highlighting the role of personalized medicine in enhancing treatment outcomes and improving patients' quality of life.

摘要

肺癌是全球最致命的癌症,在所有癌症类型中发病率最高。由于其症状不具特异性,该癌症通常在晚期才被诊断出来,因此治疗效果往往不佳。确诊后,治疗选择是一个关键阶段,会深刻影响患者的生存期。肺癌的治疗选择必须谨慎做出,要考虑肿瘤的组织学类型和基因特征。非小细胞肺癌是最常见、最复杂的类型,具有较高的突变负荷,这使得二代测序(NGS)对于识别特定突变和指导治疗至关重要。鉴于已有多种获批的靶向疗法,这种方法凸显了个性化医疗在肺癌治疗中的关键作用。尽管目前有治疗方案,但多年来,致力于开发考虑个体患者特征的新型定制药物的研究一直在发展。本文旨在概述每种类型肺癌的当前治疗方法,并介绍对新兴疗法的最新见解,强调个性化医疗在提高治疗效果和改善患者生活质量方面的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f5a/11899562/98d34135866b/cancers-17-00725-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f5a/11899562/b5d2800b2fdc/cancers-17-00725-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f5a/11899562/fe21a6c708d4/cancers-17-00725-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f5a/11899562/f08128dd6230/cancers-17-00725-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f5a/11899562/98d34135866b/cancers-17-00725-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f5a/11899562/b5d2800b2fdc/cancers-17-00725-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f5a/11899562/fe21a6c708d4/cancers-17-00725-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f5a/11899562/f08128dd6230/cancers-17-00725-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2f5a/11899562/98d34135866b/cancers-17-00725-g004.jpg

相似文献

1
Lung Cancer Therapy: The Role of Personalized Medicine.肺癌治疗:个性化医疗的作用。
Cancers (Basel). 2025 Feb 21;17(5):725. doi: 10.3390/cancers17050725.
2
The landscape of actionable genomic alterations in lung adenocarcinomas in India.印度肺腺癌中可操作的基因组改变情况
Front Genet. 2023 Dec 13;14:1256756. doi: 10.3389/fgene.2023.1256756. eCollection 2023.
3
Validity of an NGS-based multiple gene panel in identifying actionable mutations for patients with NSCLC in a Chinese hospital.基于二代测序的多基因检测 panel 在一家中国医院对非小细胞肺癌患者可操作突变的识别中的有效性。
Oncol Lett. 2019 Jun;17(6):5425-5434. doi: 10.3892/ol.2019.10265. Epub 2019 Apr 18.
4
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.在晚期非小细胞肺癌中,基于循环肿瘤 DNA 的下一代测序检测与组织下一代测序检测鉴定出的可操作基因组改变具有高度一致性:韩国肺液与有创性活检项目。
Cancer. 2021 Aug 15;127(16):3019-3028. doi: 10.1002/cncr.33571. Epub 2021 Apr 7.
5
From Genomic Exploration to Personalized Treatment: Next-Generation Sequencing in Oncology.从基因组探索到个性化治疗:肿瘤学中的下一代测序技术
Curr Issues Mol Biol. 2024 Nov 6;46(11):12527-12549. doi: 10.3390/cimb46110744.
6
Next-generation sequencing as a valuable tool for mutational spectrum in advanced-stage NSCLC patients.下一代测序作为晚期非小细胞肺癌患者突变谱分析的一种有价值的工具。
Med Pharm Rep. 2024 Jul;97(3):298-307. doi: 10.15386/mpr-2763. Epub 2024 Jul 30.
7
Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review.新兴生物标志物在非小细胞肺癌治疗中的识别与应用:系统评价
Cancers (Basel). 2024 Jun 26;16(13):2338. doi: 10.3390/cancers16132338.
8
Improving diagnostic capabilities in lung cancer through next-generation sequencing: a narrative review.通过下一代测序提高肺癌诊断能力:一篇叙述性综述
J Thorac Dis. 2025 Jan 24;17(1):476-486. doi: 10.21037/jtd-24-488. Epub 2025 Jan 22.
9
Mutation profile in liquid biopsy tested by next generation sequencing in Mexican patients with non-small cell lung carcinoma and its impact on survival.通过下一代测序对墨西哥非小细胞肺癌患者进行液体活检的突变谱及其对生存的影响。
J Thorac Dis. 2024 Jan 30;16(1):161-174. doi: 10.21037/jtd-23-1029. Epub 2024 Jan 17.
10
Advances in Personalized Oncology.个性化肿瘤学进展
Cancers (Basel). 2024 Aug 16;16(16):2862. doi: 10.3390/cancers16162862.

引用本文的文献

1
Special Issue ''Pre-Clinical Studies of Personalized Medicine for Cancer Research''.特刊“癌症研究个性化医疗的临床前研究”
Cancers (Basel). 2025 Aug 8;17(16):2607. doi: 10.3390/cancers17162607.

本文引用的文献

1
Advances in biomarkers for immunotherapy in small-cell lung cancer.小细胞肺癌免疫治疗生物标志物的进展
Front Immunol. 2024 Dec 11;15:1490590. doi: 10.3389/fimmu.2024.1490590. eCollection 2024.
2
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms.肺及肺外神经内分泌肿瘤中的Delta样配体3(DLL3)情况
NPJ Precis Oncol. 2024 Nov 19;8(1):268. doi: 10.1038/s41698-024-00739-y.
3
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.局限期小细胞肺癌放化疗后应用度伐利尤单抗。
N Engl J Med. 2024 Oct 10;391(14):1313-1327. doi: 10.1056/NEJMoa2404873. Epub 2024 Sep 13.
4
Lung cancer screening: where do we stand?肺癌筛查:我们目前的状况如何?
Breathe (Sheff). 2024 Aug 27;20(2):230190. doi: 10.1183/20734735.0190-2023. eCollection 2024 Jun.
5
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.皮下注射与静脉注射 Amivantamab,均联合 Lazertinib,治疗难治性表皮生长因子受体突变型非小细胞肺癌:III 期 PALOMA-3 研究的主要结果。
J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10.
6
Enhancing Lung Cancer Care in Portugal: Bridging Gaps for Improved Patient Outcomes.加强葡萄牙的肺癌护理:弥合差距以改善患者预后。
J Pers Med. 2024 Apr 24;14(5):446. doi: 10.3390/jpm14050446.
7
Perioperative Nivolumab in Resectable Lung Cancer.可切除肺癌的围手术期纳武利尤单抗。
N Engl J Med. 2024 May 16;390(19):1756-1769. doi: 10.1056/NEJMoa2311926.
8
Dual Drug Repurposing: The Example of Saracatinib.双重药物再利用:以萨拉替尼为例。
Int J Mol Sci. 2024 Apr 22;25(8):4565. doi: 10.3390/ijms25084565.
9
Epidemiology and Outcomes of Non-Small Cell Lung Cancer in South Korea.韩国非小细胞肺癌的流行病学和结局。
JAMA Netw Open. 2024 Feb 5;7(2):e2355331. doi: 10.1001/jamanetworkopen.2023.55331.
10
Lung Cancer in Never Smokers: Delving into Epidemiology, Genomic and Immune Landscape, Prognosis, Treatment, and Screening.非吸烟人群中的肺癌:深入探究流行病学、基因组和免疫景观、预后、治疗和筛查。
Lung. 2023 Dec;201(6):521-529. doi: 10.1007/s00408-023-00661-3. Epub 2023 Nov 16.